EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

GATA2 Mutations Predict Poor Prognosis in Transplanted Myeloid Neoplasms

Xian Zhang, Bingjie Wang iD, Yujun Dong, Qingya Wang, Qian Wang, Jialin Zhu, Qingyun Wang, Na Han, Yuan Li iD

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 28.04.2026. Verfasst von Xian Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: GATA2 Transcription Factor, Mutation, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, The Beijing Municipal Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

GATA binding protein 2 (GATA2) plays a crucial role in the differentiation, proliferation, and maintenance of hematopoietic stem cells (HSCs). GATA2 mutations have been identified in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), but the impact of somatic GATA2 mutations on prognosis remains controversial, especially on patients who undergo allogeneic hematopoietic stem cell transplantation (allo‐HSCT).

Objectives

The aim of this retrospective case–control study was to explore the prognostic significance of somatic GATA2 mutations in MDS/AML patients who underwent allo‐HSCT. Study Design Propensity score matching (PSM) analysis was used to match patients with wild‐type GATA2 as the control group (ratio 1:3). A total of 14 patients with somatic GATA2 mutations and 39 patients with wild‐type GATA2 were enrolled.

Results

The baseline characteristics were comparable between the two groups. However, patients with GATA2 mutations had a higher frequency of WT1 mutations and relapse rate ( p = 0.036 and p = 0.008, respectively). Compared to patients with wild‐type GATA2, patients with GATA2 mutations had shorter progression‐free survival (PFS) and overall survival (OS), and post‐transplant PFS ( p < 0.001, p = 0.030, and p = 0.004, respectively). Subgroup analysis showed that the PFS, OS, post‐transplant PFS, and OS of patients with GATA2 non‐zinc finger domain 1 (non‐ZF1) mutations ( p < 0.001, p = 0.004, p < 0.001, and p = 0.049, respectively), but not those of patients with somatic GATA2 ZF1 mutations, were shorter than that of patients with wild‐type GATA2. Moreover, somatic GATA2 mutations and WBC count ≥ 20.86 × 10 9 /L were independent adverse prognostic factors for PFS ( p = 0.005 and p = 0.020, respectively). Relapse before transplantation was an independent adverse prognostic factor for OS ( p = 0.009).

Conclusions

Our preliminary study revealed that somatic GATA2 mutations, especially non‐ZF1 mutations, may be associated with unfavorable outcomes in patients with MDS/AML, even for patients who underwent allo‐HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GATA2 Transcription FactorMutationHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansFemalePrognosisMaleRetrospective StudiesAdultMiddle AgedCase-Control StudiesTransplantation, HomologousYoung Adult

Stichwörter der Autor:innen

GATA2 non‐zinc finger 1 mutationallogeneic stem cell transplantationmyeloid malignancyprognosissomatic GATA2 mutations

Substanzen

GATA2 Transcription FactorGATA2 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Peking University First Hospital, Beijing, China.

ORCID-Profile: Bingjie Wang, Yuan Li

Förderung

  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation
  • The Beijing Municipal Science and Technology Commission
  • National High Level Hospital Clinical Research Funding
  • China University Industry-University-Research Innovation Fund
  • Natural Science Foundation of Beijing Municipality
  • Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park

Zitieren

APA

Zhang, X., Wang, B., Dong, Y., Wang, Q., Wang, Q., Zhu, J., Wang, Q., Han, N., & Li, Y. (2026). GATA2 Mutations Predict Poor Prognosis in Transplanted Myeloid Neoplasms. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71883

Vancouver

Zhang X, Wang B, Dong Y, Wang Q, Wang Q, Zhu J, et al. GATA2 Mutations Predict Poor Prognosis in Transplanted Myeloid Neoplasms. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71883

BibTeX
@article{Zhang2026,
  author = {Zhang, Xian and Wang, Bingjie and Dong, Yujun and Wang, Qingya and Wang, Qian and Zhu, Jialin and Wang, Qingyun and Han, Na and Li, Yuan},
  title = {GATA2 Mutations Predict Poor Prognosis in Transplanted Myeloid Neoplasms},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71883}
}
Kostenlos starten →